In this study, we demonstrated that treatment with the AhR antagonist TMF ameliorated TNF-α-enhanced VCAM-1 protein levels, monocyte binding ability, and HMCM-stimulated PD-L1 protein expression on human GBM cells. The gene discussed is TNF; the disease is glioblastoma.